论文部分内容阅读
目的 观察重组组织型纤溶酶原激活剂 (rt -PA)与尿激酶 (UK)静脉溶栓治疗急性心肌梗死 (AMI)的疗效。方法 将患者随机分为rt-PA和UK两组进行对比分析。结果 rt -PA组冠状动脉 (冠脉 )总再通率为 80 % (2 4/ 30 ) ,UK组冠脉总再通率为 6 0 % (18/ 30 ) ,患者在发病 <3h溶栓治疗 ,rt -PA组冠脉再通率为88 9% ,UK组冠脉再通率为 6 8 4% ,前者明显高于后者 ,统计学处理有显著性差异 (P <0 0 5 ) ;4周住院病死率 :rt-PA组为 6 7% ,UK组为 13 3% ,前者低于后者 ,两组对比统计学处理具有明显统计学差异 (P <0 0 1)。结论 rt-PA溶栓疗效优于UK ,尤其是在患者发病后 3h内进行溶栓治疗效果更佳 ,住院病死率低。
Objective To observe the curative effect of intravenous thrombolytic therapy of recombinant tissue plasminogen activator (rt-PA) and urokinase (UK) on acute myocardial infarction (AMI). Methods Patients were randomly divided into rt-PA and UK groups for comparative analysis. Results The total recanalization rate of coronary artery (rt-PA) was 80% (20/40) in rt-PA group and 60% (18/30) of coronary artery in UK group. Thrombolytic therapy In the rt-PA group, the rate of coronary recanalization was 88.9% and the coronary recanalization rate was 68.4% in the UK group. The former was significantly higher than the latter (P <0.05) . The 4-week in-hospital mortality was 67% in rt-PA group and 13.3% in UK group, the former was lower than the latter. There was significant statistical difference between the two groups (P <0.01). Conclusions rt-PA thrombolytic therapy is superior to UK, especially thrombolytic therapy within 3h after onset of the patient is better and hospitalization mortality is lower.